Sgp130Fc induces minor adverse effects including upper respiratory infections, recurrence of herpes labialis and skin and subcutaneous disorders, suggesting that selective inhibition of trans-signaling by sgp130Fc is superior over combined inhibition of classic and trans-signaling by antagonistic IL-6 and IL-6R antibodies. The gene discussed is IL6R; the disease is herpes labialis.